Clinical Trial
doi: 10.1007/BF01202225.
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study
Affiliations
- PMID: 7883775
- PMCID: PMC12200300
- DOI: 10.1007/BF01202225
Item in Clipboard
Clinical Trial
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study
J Cancer Res Clin Oncol.
1995.
Abstract
We investigated the potential of cross-over to the serotonin receptor (5HT3) antagonist ondansetron after protection failure with tropisetron. Several cases of complete protection were observed. These limited data suggest that there is an indication for retreatment with a different 5HT3 antagonist after an initial failure to another and also stress the need and relevance for comparative studies between 5HT3 antagonists.
Similar articles
-
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2. Cochrane Database Syst Rev. 2021. PMID: 34784425 Free PMC article.
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
-
Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):101-8. doi: 10.1080/088800199277425. Pediatr Hematol Oncol. 1999. PMID: 10100270 Clinical Trial.
-
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.Cochrane Database Syst Rev. 2016 Feb 2;2(2):CD007786. doi: 10.1002/14651858.CD007786.pub3. Cochrane Database Syst Rev. 2016. PMID: 26836199 Free PMC article.
-
Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.BMC Med. 2016 Dec 23;14(1):216. doi: 10.1186/s12916-016-0761-9. BMC Med. 2016. PMID: 28007031 Free PMC article.
Cited by
-
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.Br J Cancer. 2001 Oct 19;85(8):1099-101. doi: 10.1054/bjoc.2001.2045. Br J Cancer. 2001. PMID: 11710819 Free PMC article. Clinical Trial.
References
-
- Italian Group for Antiemetic Research (1993) Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 11: 396–2404 - PubMed
-
- Marty M, Pouillart P, Scholl S, et al. (1990) Comparison of the 5HT3 (serotonin) antagonist ondansetron (OR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–820 - PubMed
-
- Mulder PHM de, Seynaeve C, Vermoren JB, et al. (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113: 834–840 - PubMed
-
- Seynaeve C, Verweij J, Mulder P de (1991) 5 HT3 receptor antagonists, a new approach in emesis. A review on clinical results of ondansetron, granisetron and tropisetron. Anticancer Drugs 19: 203–208 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources